Mitochondrial Medicine is a relatively new area where several disciplines from basic science to clinical medicine converge. Mitochondrial medicine deals with diseases that are related to mitochondrial dysfunction due to a number of causes from free radical damage to genetic mutation. A primary feature of mitochondrial dysfunction is impaired cellular bioenergetics.

This book is based upon extensive data gathered over 30 years of clinical and experimental research. Internationally recognized authors share their experience and state-of-the-art knowledge in various fields of their expertise such as mitochondrial cardiology, neurology, diabetology, nephrology, immunology, rheumatology, reproductive medicine, sports medicine, and chronobiology, and guide readers through the disease process, from basic biochemical mechanisms to diagnosis to therapeutic aspects.

Laboratory evaluation plays a very important role in the diagnosis of mitochondrial diseases, in addition to clinical assessment. This includes analysis of plasma/mitochondrial coenzyme Q10 content, mitochondrial respiratory chain function and oxidative phosphorylation in isolated mitochondria and biopsy material, and nuclear magnetic resonance methods.

In addition to standard medical therapy to treat cardiac, CNS, and other involvements in the mitochondrial disease patients, adjunctive nutritional therapy is indicated primarily to improve mitochondrial function. Therapy include coenzyme Q10, a -lipoic acid, carnitine, w -3- and w -6-PUFA, vitamins and polarized light.

Mitochondrial Medicine is dedicated to Dr. Frederick L. Crane, discoverer of Coenzyme Q10 in 1957, and to the Celebration of 50th year of Coenzyme Q10 discovery.

This book is intended for general medical practitioners, for specialists such as cardiologists, neurologists, and diabetologists, biochemists, nutritionists, pharmacists, and also for graduate students.

Translational mitochondrial medicine applies the knowledge of experimental medicine in clinical practice, it is a prospective direction of the development of mitochondrial medicine. The monograph "Translational Mitochondrial Medicine" was created on the basis of rapidly developing new information about mitochondrial diseases and their disorders, is a revised and supplemented edition of the monographs: "Mitochondrial Medicine", ed. A. Gvozdjáková, Springer, 2008 and "Recent Advances in Mitochondrial Medicine and Coenzyme Q10", eds. A. Gvozdjáková, G. Cornélissen, RB Singh, NOVA Science, USA, 2018. The monograph was created as part of the book series "Advances in biochemistry in health and disease", edited by prof. Naranjan Dhalla of Winnipeg, for which we are grateful.

The book"Translational Mitochondrial Medicine" contributes to the elucidation of the pathobiochemical mechanisms of various diseases, provides current information on the prospective application of the latest diagnostic approaches and targeted therapy of mitochondrial diseases.

Perspective mtDNA diagnostic methods include new technologies based on NGS (Next Generation Sequencing) to identify new genes associated with mitochondrial diseases. With the help of the high resolution respirometry method (HRR), it is possible to record even the most subtle deviations of the bioenergetics of mitochondria in blood cells, it contributes to the monitoring of the used daily doses of drugs in patients with various diseases. Determination of the endogenous level of coenzyme Q10 (CoQ10) in platelets is a key method to improve the diagnosis and targeted therapy of damaged mitochondrial bioenergetics. Perspective therapeutic strategies for damaged mitochondria include mitochondrial transplantation, plasma therapy, mitochondrial nanotherapy, weight reduction in obesity, spa rehabilitation, the influence of molecular hydrogen and oxygen therapy. Targeted therapeutic methods for dysfunctional mitochondria and CoQ10 deficiency include supplementation with CoQ10, antioxidants and vitamins.

This volume is intended for researchers and physicians looking for new prospective diagnostic approaches and targeted therapies for dysfunctional mitochondria in their patients.

Mitochondrial Medicine is a relatively new area where several disciplines from basic science to clinical medicine converge. Mitochondrial medicine deals with diseases that are related to mitochondrial dysfunction due to a number of causes from free radical damage to genetic mutation. A primary feature of mitochondrial dysfunction is impaired cellular bioenergetics.

This book is based upon extensive data gathered over 30 years of clinical and experimental research. Internationally recognized authors share their experience and state-of-the-art knowledge in various fields of their expertise such as mitochondrial cardiology, neurology, diabetology, nephrology, immunology, rheumatology, reproductive medicine, sports medicine, and chronobiology, and guide readers through the disease process, from basic biochemical mechanisms to diagnosis to therapeutic aspects.

Laboratory evaluation plays a very important role in the diagnosis of mitochondrial diseases, in addition to clinical assessment. This includes analysis of plasma/mitochondrial coenzyme Q10 content, mitochondrial respiratory chain function and oxidative phosphorylation in isolated mitochondria and biopsy material, and nuclear magnetic resonance methods.

In addition to standard medical therapy to treat cardiac, CNS, and other involvements in the mitochondrial disease patients, adjunctive nutritional therapy is indicated primarily to improve mitochondrial function. Therapy include coenzyme Q10, a -lipoic acid, carnitine, w -3- and w -6-PUFA, vitamins and polarized light.

Mitochondrial Medicine is dedicated to Dr. Frederick L. Crane, discoverer of Coenzyme Q10 in 1957, and to the Celebration of 50th year of Coenzyme Q10 discovery.

This book is intended for general medical practitioners, for specialists such as cardiologists, neurologists, and diabetologists, biochemists, nutritionists, pharmacists, and also for graduate students.

Translational mitochondrial medicine applies the knowledge of experimental medicine in clinical practice, it is a prospective direction of the development of mitochondrial medicine. The monograph "Translational Mitochondrial Medicine" was created on the basis of rapidly developing new information about mitochondrial diseases and their disorders, is a revised and supplemented edition of the monographs: "Mitochondrial Medicine", ed. A. Gvozdjáková, Springer, 2008 and "Recent Advances in Mitochondrial Medicine and Coenzyme Q10", eds. A. Gvozdjáková, G. Cornélissen, RB Singh, NOVA Science, USA, 2018. The monograph was created as part of the book series "Advances in biochemistry in health and disease", edited by prof. Naranjan Dhalla of Winnipeg, for which we are grateful.

The book"Translational Mitochondrial Medicine" contributes to the elucidation of the pathobiochemical mechanisms of various diseases, provides current information on the prospective application of the latest diagnostic approaches and targeted therapy of mitochondrial diseases.

Perspective mtDNA diagnostic methods include new technologies based on NGS (Next Generation Sequencing) to identify new genes associated with mitochondrial diseases. With the help of the high resolution respirometry method (HRR), it is possible to record even the most subtle deviations of the bioenergetics of mitochondria in blood cells, it contributes to the monitoring of the used daily doses of drugs in patients with various diseases. Determination of the endogenous level of coenzyme Q10 (CoQ10) in platelets is a key method to improve the diagnosis and targeted therapy of damaged mitochondrial bioenergetics. Perspective therapeutic strategies for damaged mitochondria include mitochondrial transplantation, plasma therapy, mitochondrial nanotherapy, weight reduction in obesity, spa rehabilitation, the influence of molecular hydrogen and oxygen therapy. Targeted therapeutic methods for dysfunctional mitochondria and CoQ10 deficiency include supplementation with CoQ10, antioxidants and vitamins.

This volume is intended for researchers and physicians looking for new prospective diagnostic approaches and targeted therapies for dysfunctional mitochondria in their patients.